| On the rate and extent of drug delivery to the brain M Hammarlund-Udenaes, M Fridén, S Syvänen, A Gupta Pharmaceutical research 25 (8), 1737-1750, 2008 | 374 | 2008 |
| Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport S Syvänen, Ö Lindhe, M Palner, BR Kornum, O Rahman, B Långström, ... Drug metabolism and disposition 37 (3), 635-643, 2009 | 273 | 2009 |
| Antibody-based PET imaging of amyloid beta in mouse models of Alzheimer’s disease D Sehlin, XT Fang, L Cato, G Antoni, L Lannfelt, S Syvänen Nature communications 7 (1), 1-11, 2016 | 93 | 2016 |
| Duration and degree of cyclosporin induced P-glycoprotein inhibition in the rat blood–brain barrier can be studied with PET S Syvänen, G Blomquist, M Sprycha, AU Höglund, M Roman, O Eriksson, ... Neuroimage 32 (3), 1134-1141, 2006 | 70 | 2006 |
| Advances in PET imaging of P-glycoprotein function at the blood-brain barrier S Syvänen, J Eriksson ACS chemical neuroscience 4 (2), 225-237, 2013 | 69 | 2013 |
| Pharmacokinetic consequences of active drug efflux at the blood–brain barrier S Syvänen, R Xie, S Sahin, M Hammarlund-Udenaes Pharmaceutical research 23 (4), 705-717, 2006 | 60 | 2006 |
| Blood–brain barrier penetration of zolmitriptan—modelling of positron emission tomography data M Bergström, R Yates, A Wall, M Kågedal, S Syvänen, B Långström Journal of pharmacokinetics and pharmacodynamics 33 (1), 75-91, 2006 | 55 | 2006 |
| Bivalent brain shuttle increases antibody uptake by monovalent binding to the transferrin receptor G Hultqvist, S Syvänen, XT Fang, L Lannfelt, D Sehlin Theranostics 7 (2), 308, 2017 | 54 | 2017 |
| Delineating amyloid plaque associated neuronal sphingolipids in transgenic Alzheimer’s disease mice (tgArcSwe) using MALDI imaging mass spectrometry I Kaya, D Brinet, W Michno, S Syvänen, D Sehlin, H Zetterberg, ... ACS chemical neuroscience 8 (2), 347-355, 2017 | 41 | 2017 |
| [11 C] phenytoin revisited: synthesis by [11 C] CO carbonylation and first evaluation as a P-gp tracer in rats J Verbeek, J Eriksson, S Syvänen, M Labots, ECM de Lange, RA Voskuyl, ... EJNMMI research 2 (1), 1-11, 2012 | 37 | 2012 |
| Pharmacokinetics of P‐glycoprotein inhibition in the rat blood‐brain barrier S Syvänen, A Hooker, O Rahman, H Wilking, G Blomquist, B Långström, ... Journal of pharmaceutical sciences 97 (12), 5386-5400, 2008 | 37 | 2008 |
| Specific uptake of an amyloid-β protofibril-binding antibody-tracer in AβPP transgenic mouse brain K Magnusson, D Sehlin, S Syvänen, MM Svedberg, O Philipson, ... Journal of Alzheimer's Disease 37 (1), 29-40, 2013 | 36 | 2013 |
| Using PET studies of P-gp function to elucidate mechanisms underlying the disposition of drugs S Syvanen, M Hammarlund-Udenaes Current topics in medicinal chemistry 10 (17), 1799-1809, 2010 | 36 | 2010 |
| (R)-[11 C] Verapamil PET studies to assess changes in P-glycoprotein expression and functionality in rat blood-brain barrier after exposure to kainate-induced status epilepticus S Syvänen, G Luurtsema, CFM Molthoff, AD Windhorst, MC Huisman, ... BMC medical imaging 11 (1), 1-16, 2011 | 35 | 2011 |
| Probing amyloid‐β pathology in transgenic Alzheimer's disease (tgArcSwe) mice using MALDI imaging mass spectrometry L Carlred, W Michno, I Kaya, P Sjövall, S Syvänen, J Hanrieder Journal of neurochemistry 138 (3), 469-478, 2016 | 34 | 2016 |
| (R)-[C-11] PK11195 brain uptake as a biomarker of inflammation and antiepileptic drug resistance: Evaluation in a rat epilepsy model RM Bogdanovic, S Syvanen, C Michler, V Russmann, J Eriksson, ... Neuropharmacology 85, 104-112, 2014 | 34 | 2014 |
| Altered GABAA receptor density and unaltered blood–brain barrier transport in a kainate model of epilepsy: an in vivo study using 11C-flumazenil and PET S Syvänen, M Labots, Y Tagawa, J Eriksson, AD Windhorst, ... Journal of Nuclear Medicine 53 (12), 1974-1983, 2012 | 32 | 2012 |
| A bispecific Tribody PET radioligand for visualization of amyloid-beta protofibrils–a new concept for neuroimaging S Syvänen, XT Fang, G Hultqvist, SR Meier, L Lannfelt, D Sehlin Neuroimage 148, 55-63, 2017 | 26 | 2017 |
| [11C] quinidine and [11C] laniquidar PET imaging in a chronic rodent epilepsy model: impact of epilepsy and drug-responsiveness S Syvänen, V Russmann, J Verbeek, J Eriksson, M Labots, C Zellinger, ... Nuclear medicine and biology 40 (6), 764-775, 2013 | 26 | 2013 |
| Effect on [11C]DASB binding after tranylcypromine‐induced increase in serotonin concentration: Positron emission tomography studies in monkeys and rats P Lundquist, M Roman, S Syvänen, P Hartvig, G Blomquist, ... Synapse 61 (6), 440-449, 2007 | 26 | 2007 |
Dag SehlinAssociate professor, Uppsala universityVerified email at pubcare.uu.se
